Mannitol for Childhood Cerebral Malaria
Author Information
Author(s): Namutangula Beatrice, Ndeezi Grace, Byarugaba Justus S, Tumwine James K
Primary Institution: Makerere University Medical School
Hypothesis
Does intravenous mannitol improve clinical outcomes in children with cerebral malaria?
Conclusion
Mannitol had no significant impact on the clinical outcome of cerebral malaria.
Supporting Evidence
- Time to regain consciousness was similar between mannitol and placebo groups.
- Mortality rates were not significantly different between the two groups.
- No adverse effects were observed after administration of mannitol.
Takeaway
The study tested if a medicine called mannitol could help kids with a serious brain infection called cerebral malaria, but it didn't make a difference.
Methodology
A randomized double-blind placebo-controlled trial was conducted with 156 children aged 6 to 60 months with cerebral malaria, comparing mannitol to placebo in addition to intravenous quinine.
Potential Biases
Potential bias due to imprecise diagnosis of cerebral malaria.
Limitations
The study may not have been powered to detect differences in mortality, and intracranial pressure was not measured.
Participant Demographics
Children aged 6 to 60 months with cerebral malaria.
Statistical Information
Confidence Interval
CI 0.5–2.7
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website